MedTrace Logo

Early Changes in OCT Biomarkers After the First Intravitreal Anti-VEGF Injection in Treatment-naïve DME

NCT06841250 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-02-24

No results posted yet for this study

Summary

A retrospective, observational, hospital-based study which will be conducted in the Department of Ophthalmology, Sohag University Hospital, Egypt.

Conditions

  • Early OCT Biomarker Changes in Response to Anti-VEGF

Interventions

PROCEDURE

intravitreal injection of anti-VEGF

Ranibizumab is injected into the vitreous under aseptic conditions as part of routine DME treatment

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-16
Primary Completion
2026-01-16
Completion
2026-01-16
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06841250 on ClinicalTrials.gov